JP2024545572A5 - - Google Patents

Info

Publication number
JP2024545572A5
JP2024545572A5 JP2024527340A JP2024527340A JP2024545572A5 JP 2024545572 A5 JP2024545572 A5 JP 2024545572A5 JP 2024527340 A JP2024527340 A JP 2024527340A JP 2024527340 A JP2024527340 A JP 2024527340A JP 2024545572 A5 JP2024545572 A5 JP 2024545572A5
Authority
JP
Japan
Prior art keywords
mrna
composition according
optionally
dnai1
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545572A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079650 external-priority patent/WO2023086893A1/en
Publication of JP2024545572A publication Critical patent/JP2024545572A/ja
Publication of JP2024545572A5 publication Critical patent/JP2024545572A5/ja
Pending legal-status Critical Current

Links

JP2024527340A 2021-11-10 2022-11-10 原発性線毛機能不全の治療のための組成物及び方法 Pending JP2024545572A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278007P 2021-11-10 2021-11-10
US63/278,007 2021-11-10
PCT/US2022/079650 WO2023086893A1 (en) 2021-11-10 2022-11-10 Composition and methods for treatment of primary ciliary dyskinesia

Publications (2)

Publication Number Publication Date
JP2024545572A JP2024545572A (ja) 2024-12-10
JP2024545572A5 true JP2024545572A5 (cg-RX-API-DMAC10.html) 2025-11-17

Family

ID=84829874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527340A Pending JP2024545572A (ja) 2021-11-10 2022-11-10 原発性線毛機能不全の治療のための組成物及び方法

Country Status (6)

Country Link
US (1) US20240415866A1 (cg-RX-API-DMAC10.html)
EP (1) EP4429713A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024545572A (cg-RX-API-DMAC10.html)
CN (1) CN118591398A (cg-RX-API-DMAC10.html)
AU (1) AU2022388747A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023086893A1 (cg-RX-API-DMAC10.html)

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EA022786B1 (ru) 2009-07-31 2016-03-31 Этрис Гмбх Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
BR112014024131A2 (pt) 2012-03-29 2017-07-25 Shire Human Genetic Therapies lipídios catiônicos ionizáveis
EA201591283A1 (ru) 2013-03-14 2016-02-29 Шир Хьюман Дженетик Терапис, Инк. Количественная оценка эффективности кэп матричной рнк
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP4729528A3 (en) 2014-04-25 2026-06-24 Translate Bio, Inc. Methods for purification of messenger rna
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016004318A1 (en) 2014-07-02 2016-01-07 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
CA3025626A1 (en) * 2016-05-27 2017-11-30 Transcriptx, Inc. Treatment of primary ciliary dyskinesia with synthetic messenger rna
CN116549671A (zh) 2016-11-10 2023-08-08 川斯勒佰尔公司 用于递送mrna的改进的基于ice的脂质纳米颗粒制剂
US20180153822A1 (en) 2016-11-10 2018-06-07 Translate Bio, Inc. Process of Preparing mRNA-Loaded Lipid Nanoparticles
IL310939B2 (en) 2017-02-27 2026-01-01 Translate Bio Inc Large-scale production of therapeutic preparations enriched with mRNA encoding therapeutic peptides
IL268856B2 (en) 2017-02-27 2024-09-01 Translate Bio Inc Methods for purification of messenger rna
ES2899323T3 (es) 2017-02-27 2022-03-10 Translate Bio Inc Métodos de purificación de ARN mensajero
WO2020146344A1 (en) * 2019-01-07 2020-07-16 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2021226463A1 (en) * 2020-05-07 2021-11-11 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
IL305958A (en) * 2021-03-22 2023-11-01 Recode Therapeutics Inc Polynucleotide preparations, related formulations and methods of using them

Similar Documents

Publication Publication Date Title
JP2024028651A5 (cg-RX-API-DMAC10.html)
JP2022516356A5 (cg-RX-API-DMAC10.html)
US12533402B2 (en) MRNA therapy for argininosuccinate synthetase deficiency
EP3624824B1 (en) Codon-optimized mrna encoding cftr for use in treating cystic fibrosis
US20220048867A1 (en) Stereochemically enriched compositions for delivery of nucleic acids
JP2016539916A5 (cg-RX-API-DMAC10.html)
JP2019073557A5 (cg-RX-API-DMAC10.html)
US20240009281A1 (en) Mrna therapy for pompe disease
US10835583B2 (en) Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
US9522176B2 (en) MRNA therapy for phenylketonuria
JP2016535729A5 (cg-RX-API-DMAC10.html)
JP2016534992A5 (cg-RX-API-DMAC10.html)
US20190192688A1 (en) Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency
JP2017520563A5 (cg-RX-API-DMAC10.html)
JP2016535738A5 (cg-RX-API-DMAC10.html)
US10780183B2 (en) Messenger RNA therapy for the treatment of Friedreich's ataxia
CN112533909A (zh) 维生素阳离子脂质
AU2022381463A1 (en) Lipid nanoparticles for oligonucleotide delivery
US20230226147A1 (en) Composition and methods for treatment of primary ciliary dyskinesia
JP2018511588A5 (cg-RX-API-DMAC10.html)
JP2017518371A5 (cg-RX-API-DMAC10.html)
AU2014340083A1 (en) mRNA therapy for phenylketonuria
US20230190954A1 (en) Composition and methods for treatment of primary ciliary dyskinesia
JP2024540101A (ja) オリゴヌクレオチド送達のための脂質ナノ粒子
JP2024545572A (ja) 原発性線毛機能不全の治療のための組成物及び方法